

Western Australian Immunisation Schedule

Childhood

Age and eligibility	Antigen/Antibody	Brand(s)	Important information
Birth to <7 days	Nirsevimab*	Beyfortus®	Can be given up to 8 months of age, but preferably as close to birth as possible, if the mother did not receive Abrysvo > 2 weeks prior to birth. See RSV table and links below for further information.
	Hepatitis B	H-B-Vax® II Paed or Engerix® B Paed	
6-8 weeks	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®	
	13vPCV	Prevenar® 13	
	Rotavirus	Rotarix®	Oral dose 1: Must be given by 14 weeks of age
Aboriginal*and/or MRC	MenACWY	Nimenrix®	
Aboriginal and/or MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
4 months	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®	
	13vPCV	Prevenar® 13	
	Rotavirus	Rotarix®	Oral dose 2: Must be given by 24 weeks of age
Aboriginal*and/or MRC	MenACWY	Nimenrix®	
Aboriginal and/or MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
6 months	DTPa-hepB-IPV-Hib	Infanrix® hexa or Vaxelis®	
Aboriginal and/or MRC	13vPCV	Prevenar® 13	
MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
	MenACWY	Nimenrix®	
12 months	MMR	Priorix® or M-M-R II®	The 2 brands of MMR vaccine are interchangeable
	13vPCV	Prevenar® 13	
	MenACWY	Nimenrix®	
Aboriginal and/or MRC	MenB	Bexsero®	Prophylactic paracetamol recommended
MRC	Hepatitis B	H-B-Vax® II Paed or Engerix® B Paed	<32 weeks gestation or <2000g birth weight
18 months	DTPa	Infanrix® or Tripacel®	
	Hib	ActHIB®	
	MMRV	Priorix-Tetra®	Do not administer MMRV as dose 1 of a measles-containing vaccine if <4 years of age
Aboriginal	Hepatitis A	Vaqa® Paed/Adol	Dose 1 of 2. Dose 2 to be administered at least 6 months after dose 1
<2 years	Catch-up for MenB is available for Aboriginal children <2 years of age		
Aboriginal			
4 years	DTPa-IPV	Quadracel® or Infanrix® IPV	
Aboriginal	Hepatitis A	Vaqa® Paed/Adol	Not required if previously received 2 doses (first dose at age ≥12 months) at least 6 months apart
Aboriginal and/or MRC	23vPPV	Pneumovax23®	Dose 1 (if not previously administered). Dose 2 should be administered at least 5 years later

Respiratory Syncytial Virus (RSV)

Age and eligibility	Antigen/Antibody	Brand(s)	Important information
See here for WA state-wide eligibility, excluding Kimberley/ Pilbara regions. See here for Kimberley and Pilbara regions eligibility only.	Nirsevimab*	Beyfortus®	The RSV Immunisation decision aid contains information on both Abrysvo for patients currently pregnant, and Beyfortus for children under 2 years of age.

Adolescent and adult

Age and eligibility	Antigen	Vaccine brand(s)	Important information
Year 7	HPV	Gardasil®9	Catch-up for adolescents <26 years of age
	dTpa	Boostrix® or Adacel®	
Year 10	MenACWY	Nimenrix® or MenQuadfi®	
≥18 years MRC	Herpes-zoster	Shingrix®	2 doses, given 1–2 months apart
Pregnant	dTpa	Boostrix® or Adacel®	Each pregnancy, ideally between 20–32 weeks
	RSV	Abrysvo®	Eligible women between 28 - 36 weeks
≥20 years Aboriginal*	Hepatitis B	Engerix® B	For non-immune persons. See the Australian Immunisation Handbook for recommendations and timing of doses
Adult refugees and humanitarian entrants	dTpa (Boostrix® or Adacel®), HepB (H-B-Vax® II or Engerix® B), IPV (IPOL®), MMR (MMRII® or Priorix®), VZV (Varivax®). HPV (Gardasil®9) <26 years of age		See the Australian Immunisation Handbook for timing of doses
≥50 years Aboriginal	13vPCV 23vPPV	Prevenar® 13 Pneumovax23®	See the Australian Immunisation Handbook for timing of doses
	Herpes-zoster	Shingrix®	2 doses, given 2–6 months apart
Born after 1965*	MMR	Priorix® or M-M-R II®	Give 1 or 2 doses as required. Whilst serology is not routinely recommended, see WA adult measles vaccination program for details. The 2 brands of MMR vaccine are interchangeable
≥65 years	Herpes-zoster	Shingrix®	2 doses, given 2–6 months apart
≥70 years	13vPCV	Prevenar® 13	

All individuals diagnosed with **specified MRC** aged >12 months of age require 1 dose of 13vPCV at diagnosis, followed by a first dose of 23vPPV, 2 to 12 months later or at 4 years of age, whichever is later. A second dose is given at least 5 years later

Additional *Haemophilus influenzae* type b (Hib), meningococcal and pneumococcal vaccines are recommended for people with specified risk conditions. Refer to the [Australian Immunisation Handbook](#) for details

Age and eligibility	Vaccine brand(s)	Important information
6 Months to <5 Years	Vaxigrip®Tetra, FluQuadri®	For children <9 years, or persons following a stem cell or solid organ transplant, 2 doses are required 1 month apart in the first year they receive influenza vaccine. One dose annually in subsequent years. For information on influenza dosing see the Australian Immunisation Handbook or annual ATAGI advice on seasonal influenza vaccines.
≥5 Years to Year 6*	FluQuadri®	
5 Years to <65 Years	Flucelvax®Quad, Vaxigrip®Tetra	
Aboriginal and/or MRC	Flucelvax®Quad, Vaxigrip®Tetra	
Vulnerable cohorts* 12 to <65 Years	FluQuadri®	For non-NIP eligible residents in congregate living and people experiencing homelessness.
Pregnancy	Vaxigrip®Tetra, Flucelvax®Quad	Each pregnancy, any trimester
All West Australians 12 to <65 years*	FluQuadri®	Eligibility under Free Influenza Program May and June 2025
≥65 Years	Fluad® Quad	Preferentially use adjuvanted QIV
WA Health staff^	Flucelvax®Quad, FluQuadri®, Fluad® Quad	For ≥65 years use Fluad® Quad

*Refers to WA State-funded Programs.

^Refers to all persons attending WA Health staff influenza vaccination services.

The term '**Aboriginal**' is inclusive of all Aboriginal and Torres Strait Islander people.

MRC refers to people with medical risk conditions. Refer to the current online edition of the [Australian Immunisation Handbook](#) for all medical risk conditions, recommendations and timing of doses.

Persons aged <20 years can catch-up scheduled vaccines, refer to [Australian Immunisation Handbook](#) for timing of doses.